共 50 条
- [21] Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (52) : 21360 - 21365Qi, WeiChan, HoManTeng, LinLi, LingChuai, ShannonZhang, RuipengZeng, JueLi, MinFan, HongLin, YingGu, JustinArdayfio, OpheliaZhang, Ji-HuYan, XiaoxiaFang, JialuoMi, YuanZhang, ManZhou, TaoFeng, GraceChen, ZijunLi, GuobinYang, TeddyZhao, KehaoLiu, XianghuiYu, ZhengtianLu, Chris X.Atadja, PeterLi, En
- [22] The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitorCHEMICAL COMMUNICATIONS, 2021, 57 (24) : 3006 - 3009Zhang, QiangshengHu, XiLi, LuZhang, LidanWan, GuoquanFeng, QiangZhu, YongxiaWang, NingyuLiu, ZhihaoYu, Luoting
- [23] Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (12): : 1091 - 1096Verma, Sharad K.Tian, XinrongLaFrance, Louis V.Duquenne, CelineSuarez, Dominic P.Newlander, Kenneth A.Romeril, Stuart P.Burgess, Joelle L.Grant, Seth W.Brackley, James A.Graves, Alan P.Scherzer, Daryl A.Shu, ArtThompson, ChristineOtt, Heidi M.Van Aller, Glenn S.Machutta, Carl A.Diaz, ElsieJiang, YongJohnson, Neil W.Knight, Steven D.Kruger, Ryan G.McCabe, Michael T.Dhanak, DashyantTummino, Peter J.Creasy, Caretha L.Miller, William H.
- [24] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersNATURE MEDICINE, 2015, 21 (03) : 231 - +Bitler, Benjamin G.Aird, Katherine M.Garipov, AzatLi, HuaAmatangelo, MichaelKossenkov, Andrew V.Schultz, David C.Liu, QinShih, Ie-MingConejo-Garcia, Jose R.Speicher, David W.Zhang, Rugang
- [25] Discovery and synthesis of highly potent and selective small molecule inhibitors of the histone methyltransferase EZH2CANCER RESEARCH, 2012, 72Verma, Sharad K.LaFrance, Louis V.Tian, XinrongNewlander, KenDuguenne, CelineSuarez, DominicKnight, Steven D.Burgess, JoelleBrackley, JamesJohnson, Neil W.Graves, Alan R.Mellinger, MarkRomeril, StuartGrant, Seth W.Scherzer, DarylShu, ArtCreasy, Caretha L.Kruger, RyanDiaz, ElsieLe, BaochauThompson, ChristineMorgan-Ott, HeidiMcCabe, Michael T.McHugh, Charles F.Miller, William H.Tummino, PeterDhanak, Dash
- [26] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersNature Medicine, 2015, 21 : 231 - 238Benjamin G BitlerKatherine M AirdAzat GaripovHua LiMichael AmatangeloAndrew V KossenkovDavid C SchultzQin LiuIe-Ming ShihJose R Conejo-GarciaDavid W SpeicherRugang Zhang
- [27] Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma modelsCANCER RESEARCH, 2018, 78 (13)Drew, Allison E.Motwani, VinnyEichinger, LindseySmith, JesseRaimondi, Alejandra
- [28] The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438)EUROPEAN JOURNAL OF CANCER, 2014, 50 : 92 - 92Kuntz, K.Keilhack, H.Pollock, R.Knutson, S.Warholic, N.Richon, V.Chesworth, R.Copeland, R.Porter-Scott, M.Sneeringer, C.Wigle, T.
- [29] Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemiaBLOOD, 2015, 125 (02) : 346 - 357Xu, BowenOn, Doan M.Ma, AnqiParton, TrevorKonze, Kyle D.Pattenden, Samantha G.Allison, David F.Cai, LingRockowitz, ShiraLiu, ShichongLiu, YingLi, FenglingVedadi, MasoudFrye, Stephen V.Garcia, Benjamin A.Zheng, DeyouJin, JianWang, Gang Greg
- [30] Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphomaEUROPEAN JOURNAL OF CANCER, 2014, 50 : 197 - 197Ribrag, V.Soria, J. C.Reyderman, L.Chen, R.Salazar, P.Kumar, N.Kuznetsov, G.Keilhack, H.Ottesen, L. H.Italiano, A.